Novo Nordisk has moved quickly to file for approval of a new, higher-dose version of its obesity therapy Wegovy as it tries to fend off a growing challenge in the market from arch-rival Eli Lilly.

Bayer has filed for approval in the US for elinzanetant as a non-hormonal treatment for menopausal symptoms such as hot flushes, with a rival therapy from Astellas in its sights. The FDA submission is ...